Photocure's Strategic Advances with AssureMDx and Medicare Coverage Expectations

Photocure ASA, recognized as a leading entity in the bladder cancer sector, has unveiled critical developments regarding its product, AssureMDx™, and the Medicare coverage landscape following its acquisition of Vesica Health in June 2026. This move is central to the company’s strategy to enhance diagnostic processes for bladder cancer, a disease characterized by its high recurrence rate and significant health care costs.

Since the acquisition closure, Photocure has actively refined its commercial and reimbursement strategies for AssureMDx. Initial discussions with pricing authorities have yielded positive signals, suggesting potential reimbursement levels that exceed expectations set during the acquisition. AssureMDx has also received the FDA Breakthrough Device Designation in February 2026, an important endorsement that strengthens its clinical and regulatory standing. However, the processes concerning Medicare pricing and coverage are distinct and operate on different timelines. The Centers for Medicare & Medicaid Services (CMS) is projected to finalize pricing determinations by the end of 2026, effective January 1, 2027.

At the time of the acquisition, Photocure anticipated that Medicare coverage for AssureMDx would be delayed until 2028, contingent upon the submission of additional clinical evidence. However, a proposed Local Coverage Determination (LCD) by Novitas in May 2026 suggested a possibility for earlier coverage decisions. Unfortunately, the recently issued LCD on November 6, 2026, did not include AssureMDx, highlighting the necessity for further clinical evidence to support reconsideration of coverage in the future. As such, Photocure's timeline for anticipated Medicare coverage is consistent with original projections from the acquisition.

The clinical validation surrounding AssureMDx is robust, comprising extensive published studies that underscore its diagnostic capabilities, particularly in patients experiencing microhematuria. One of the most significant studies showcased that AssureMDx could potentially spare up to 89% of these patients from the invasive cystoscopy procedure while successfully detecting all cases of upper-tract urothelial cancers within the study cohort. Furthermore, the American Urological Association and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/SUFU) have recognized AssureMDx by including it in their microhematuria guidelines, further validating its clinical relevance.

In terms of ongoing research, Photocure is involved in the SeARCH study, a randomized controlled trial initiated by Erasmus University Medical Center in the Netherlands, aimed at evaluating the clinical utility of AssureMDx in diagnostic processes. The study, which includes around 1,100 microhematuria patients, is supported by grants and aligns with the company’s broader strategy to strengthen the evidence base for AssureMDx. Additionally, Photocure is in the process of finalizing a protocol for PATHWAY, a U.S.-based clinical utility study. This study aims to generate further evidence within the same patient population, reinforcing the clinical validity of AssureMDx prior to resuming conversations with the Novitas medical review team.

Dan Schneider, President and CEO of Photocure, emphasizes the importance of the ongoing research, stating, “We are encouraged by the recognition of AssureMDx's diagnostic performance in the published clinical literature and AUA/SUFU guidelines. The advances we are making in our pricing and commercial reimbursement strategy also play a crucial role as we strive to provide the evidence necessary for future Medicare coverage.”

While the latest LCD does set back immediate coverage expectations, it does not hinder the commercialization of AssureMDx via commercial payer channels, and Photocure intends to aggressively pursue these routes. They continue to maintain their forecast for initial revenue from AssureMDx in 2027, aligning with their broader mission to advance precision diagnostics in uro-oncology.

As bladder cancer remains one of the most common cancers globally, a significant portion of the patient population experiences the burden and challenges posed by multiple cystoscopy procedures. AssureMDx stands to change the diagnostic landscape and management of this disease, ultimately improving patient outcomes and streamlining healthcare expenditures. As these developments unfold, Photocure continues to prioritize the necessity of generating high-caliber clinical evidence while navigating regulatory landscapes effectively.

For further inquiries, stakeholders can reach out to Photocure's representatives, as noted in the announcements. The commitment to transparency and continuous improvement in urological care remains paramount as the company progresses in its mission to drive innovation in bladder cancer diagnostics.